CA2037434A1 - Functional assay for determining the protein s activity - Google Patents
Functional assay for determining the protein s activityInfo
- Publication number
- CA2037434A1 CA2037434A1 CA002037434A CA2037434A CA2037434A1 CA 2037434 A1 CA2037434 A1 CA 2037434A1 CA 002037434 A CA002037434 A CA 002037434A CA 2037434 A CA2037434 A CA 2037434A CA 2037434 A1 CA2037434 A1 CA 2037434A1
- Authority
- CA
- Canada
- Prior art keywords
- protein
- reagent
- clotting
- activator
- heparin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/4609—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates from reptiles
- G01N2333/4613—Snake venom
- G01N2333/462—Snake venom from Agkistrodon sp., e.g. acutase, ACTE
- G01N2333/4626—Snake venom from Agkistrodon sp., e.g. acutase, ACTE from Agkistrodon contortrix contortrix (copperhead snake); Protac (R)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/745—Assays involving non-enzymic blood coagulation factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
- G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
- G01N2333/96461—Protein C (3.4.21.69)
Abstract
BEHRINGWERKE AKTIENGESELISCHAFT HOE 9D/B 009 - Ma 819 Dr. Pfe/Zi Abstract Functional assay for determining the protein S activity The invention relates to a method for the functional determination of protein S in liquids, in particular in plasma, and to a reagent suitable for this.
Description
21~7~3~
BEHRI~GW~RRE AXTI~NGRS~LL~CHAET HOE 90/B 009 - Na 819 Dr. P~e/Zi Functional a~sayL~or determinin~ the ~rotein S activi~
The invention relates to a method for the functional determination of protein S in liquids, in par~icular in plasma, and to a reagen~ ~uitable for this.
Protein S is an inhibitor of blood clotting and acts as a cofactor of activated protein C in its proteolytic degradation of the clotting factors Va and VIIIa.
An inborn or acquired deficiency in protein S can lead to thromboembolic complications.
Protein S is syn~hesized in the liver (5tern, D. et al.
(1986), J. Cell Biol. 102, 1971-1978). The biosynthesi~
is vitamin R-dependent and the concentration in the blood is therefore reduced on treatment with vitamin R
antagonists. The star~ of the treatment can, in the presence of a protein S deficiency, lead to serious Lmpairment of the health of the patient (Grimaudo, V. et al. (1989) BMJ 298, 233-234).
The activity may also be reduced in the case of dis-seminated intravasal clotting or thromboembolic diseases.
It is clear from the abovementioned fin~ings that protein S has a decisive influence on the capability of the protein C/thrombomodulin inhibitor system, and that a reliable diagnostic system is correspondingly required.
In plasma, only about 40~ of the protein S is prese~t in the free form. The rest of about 60% is in a complex with the C4b-binding protein (Dahlback, B. (1981), Proc. Natl.
Acad. Sci. 78" 2512-2516~.
This bound protein S is not available as cofactor for activated pro1ein C and therefore has no anticoagulatory ~37~3~
action. An excessive proportion of bound protein S can therefore also be found as a functional deficiency, while the antigen is found to be normal or nearly normal (Comp, P.C. et al. (1986), Blood 67, 51)4-508; Girolami, 5. et al. (1989), Thromb. H emost. 61, 144-147).
On the other hand, the acti~ity can be normal in the case of reduced protein S antigen if only a very ~mall propor-tion is present in the inactive bound form, as is normally the case in newborns (Schwarz, H.P. et al.
(1988~, Blood 71, 562-565).
It is known to determine pro~ein S immunologically.
However, these methods do not provide any information on the activity of the protein and are not a subject of the invention.
Methods for determining the activity of protein S have also been de~cribed.
DE 3724443 A1 describes a me~hod for determining the activity of protein S. This assay requires relatively complex reagents, such as a synthetic substrate plasma, purified factor Xa and pro~hrombin, and is inconvenient to carry out due to the incubation times. Also, it is interfered with by, e.g., heparin in the sample.
~E 3607559 Al mentions a functional determination of protein S in combination with protein C. It is necessary to determine a reference value ~ithout protein C
activator for each sample. The use of an activator of F VII or F II is also claimed but no further evidence is shown. Data on the measurements to be expected or inter-fering influences for all the test systems are not given.
A functional assay i6 described by Comp, P.C. et al. in J. Clin. Invest:. 74, 2082-2088 (1984). Here the prolo~ga-tion of the clotting tLme by activated protein C is measured in the l-step factor Xa assay. $his assay is ~3 ;7~3~
relatively insensitive having a prolongation of only 24 sec for the maximum concentration of 50% which can be measured with this method. It was not possible to measure plasmas from patients under vitamin R antagonist treat-S ment or ha~ing liver damage.
Bertina et al. (Thromb. Haemost. 1985, 53 (2), 268-272) indicate a possibility of de~ermining functional protein S in human plasma. However, the test cannot b~ evaluated quantitatively for protein S insofar as there is no pos-sib~e control of the endogenous factor VIII or factor Vin the plasma to be measured and the prolongations depend decisively on these two factors. If these factors are present in the sample in an increased or reduced con-centration, findings which are correspondingly reduced or increased result for protein S.
Van de Waart et al. (1987, Thromb. Res. 48, 427-437) use a system comprising adsorbed substrate plasma, added prothrombin, activated protein C, phospholipids and calcium chloride. A 100% difference in the protein S
content of the sample only cause about 20 seconds o~
prolongation, i.e. the assay is likewise relatively insensitive.
Suzuki K. and Nishioka J. (1988, Thromb. Res. 49, 241-251) describe a further assay system. They use Protaca, an activator for protein C from snake venom. This method is also time-consuming and inconvenient. The sensitivity is very low at a prolongation of 13 sec for a 100~ dif-ference in acti~ity.
Kobayashi I. et al. (1989, Clin. Chem. 35, 1644-1648) also propose a protein S assay which likewise represents a determination via a modified aPTT determination.
The test methods known hitherto have in common that, in addition to an inconvenient procedure because of the multiplicity of reagents used, they only have a low ~ 4 - 2 ~ 3 ~
sensitivity which is measured by the prolongation of the reaction time in relation ~o the degree of protein S
activity.
It was therefore an object of the invention to develop a method and a reagent which allows the determination of the activity of protein S in plaæma in both a simple and a reliable, sensitive and specific way.
According to the inven~ion, a method for determining protein S by measuring the clotting time of a biological sample is now disclosed, wherein the amount of added activators is adjusted in such a way that the clotting time is prolonged beyond the normal clotting ~ime.
Prolonging the ~lotting time made it possible in a surprisingly simple way to achieve a very great increase in sensitivity which can, moreover, be adapted to the requirements.
Methods for determining the clotting time are known per se to those ~killed in the art. They can, inter alia, be methods which determine the liberation of thrombin from prothrombin via the formation of a clot or the conYersion of a chromogenic substrate. The preferred method in this - connection is the chromogenic one, with a ~ery particular preference for the use of a chromogenic thrombin sub-strate, in particular of Tos-Gly-Pro-Arg-ANBA-IPA.
In a preferred embodLment of the method according to the invention, an excess of protein S-deficient plasma is added to the undiluted sample and the clotting time is then determined by admixing a reagent comprising activated protein C, an activator of the exogenous or endogenous path of clotting, phospholipids, Ca~, a chromogenic substrate for thrombin and a heparin neutralizing substance. The activated protein C can also be added to the sample separately a short time before the rest of the reagent.
BEHRI~GW~RRE AXTI~NGRS~LL~CHAET HOE 90/B 009 - Na 819 Dr. P~e/Zi Functional a~sayL~or determinin~ the ~rotein S activi~
The invention relates to a method for the functional determination of protein S in liquids, in par~icular in plasma, and to a reagen~ ~uitable for this.
Protein S is an inhibitor of blood clotting and acts as a cofactor of activated protein C in its proteolytic degradation of the clotting factors Va and VIIIa.
An inborn or acquired deficiency in protein S can lead to thromboembolic complications.
Protein S is syn~hesized in the liver (5tern, D. et al.
(1986), J. Cell Biol. 102, 1971-1978). The biosynthesi~
is vitamin R-dependent and the concentration in the blood is therefore reduced on treatment with vitamin R
antagonists. The star~ of the treatment can, in the presence of a protein S deficiency, lead to serious Lmpairment of the health of the patient (Grimaudo, V. et al. (1989) BMJ 298, 233-234).
The activity may also be reduced in the case of dis-seminated intravasal clotting or thromboembolic diseases.
It is clear from the abovementioned fin~ings that protein S has a decisive influence on the capability of the protein C/thrombomodulin inhibitor system, and that a reliable diagnostic system is correspondingly required.
In plasma, only about 40~ of the protein S is prese~t in the free form. The rest of about 60% is in a complex with the C4b-binding protein (Dahlback, B. (1981), Proc. Natl.
Acad. Sci. 78" 2512-2516~.
This bound protein S is not available as cofactor for activated pro1ein C and therefore has no anticoagulatory ~37~3~
action. An excessive proportion of bound protein S can therefore also be found as a functional deficiency, while the antigen is found to be normal or nearly normal (Comp, P.C. et al. (1986), Blood 67, 51)4-508; Girolami, 5. et al. (1989), Thromb. H emost. 61, 144-147).
On the other hand, the acti~ity can be normal in the case of reduced protein S antigen if only a very ~mall propor-tion is present in the inactive bound form, as is normally the case in newborns (Schwarz, H.P. et al.
(1988~, Blood 71, 562-565).
It is known to determine pro~ein S immunologically.
However, these methods do not provide any information on the activity of the protein and are not a subject of the invention.
Methods for determining the activity of protein S have also been de~cribed.
DE 3724443 A1 describes a me~hod for determining the activity of protein S. This assay requires relatively complex reagents, such as a synthetic substrate plasma, purified factor Xa and pro~hrombin, and is inconvenient to carry out due to the incubation times. Also, it is interfered with by, e.g., heparin in the sample.
~E 3607559 Al mentions a functional determination of protein S in combination with protein C. It is necessary to determine a reference value ~ithout protein C
activator for each sample. The use of an activator of F VII or F II is also claimed but no further evidence is shown. Data on the measurements to be expected or inter-fering influences for all the test systems are not given.
A functional assay i6 described by Comp, P.C. et al. in J. Clin. Invest:. 74, 2082-2088 (1984). Here the prolo~ga-tion of the clotting tLme by activated protein C is measured in the l-step factor Xa assay. $his assay is ~3 ;7~3~
relatively insensitive having a prolongation of only 24 sec for the maximum concentration of 50% which can be measured with this method. It was not possible to measure plasmas from patients under vitamin R antagonist treat-S ment or ha~ing liver damage.
Bertina et al. (Thromb. Haemost. 1985, 53 (2), 268-272) indicate a possibility of de~ermining functional protein S in human plasma. However, the test cannot b~ evaluated quantitatively for protein S insofar as there is no pos-sib~e control of the endogenous factor VIII or factor Vin the plasma to be measured and the prolongations depend decisively on these two factors. If these factors are present in the sample in an increased or reduced con-centration, findings which are correspondingly reduced or increased result for protein S.
Van de Waart et al. (1987, Thromb. Res. 48, 427-437) use a system comprising adsorbed substrate plasma, added prothrombin, activated protein C, phospholipids and calcium chloride. A 100% difference in the protein S
content of the sample only cause about 20 seconds o~
prolongation, i.e. the assay is likewise relatively insensitive.
Suzuki K. and Nishioka J. (1988, Thromb. Res. 49, 241-251) describe a further assay system. They use Protaca, an activator for protein C from snake venom. This method is also time-consuming and inconvenient. The sensitivity is very low at a prolongation of 13 sec for a 100~ dif-ference in acti~ity.
Kobayashi I. et al. (1989, Clin. Chem. 35, 1644-1648) also propose a protein S assay which likewise represents a determination via a modified aPTT determination.
The test methods known hitherto have in common that, in addition to an inconvenient procedure because of the multiplicity of reagents used, they only have a low ~ 4 - 2 ~ 3 ~
sensitivity which is measured by the prolongation of the reaction time in relation ~o the degree of protein S
activity.
It was therefore an object of the invention to develop a method and a reagent which allows the determination of the activity of protein S in plaæma in both a simple and a reliable, sensitive and specific way.
According to the inven~ion, a method for determining protein S by measuring the clotting time of a biological sample is now disclosed, wherein the amount of added activators is adjusted in such a way that the clotting time is prolonged beyond the normal clotting ~ime.
Prolonging the ~lotting time made it possible in a surprisingly simple way to achieve a very great increase in sensitivity which can, moreover, be adapted to the requirements.
Methods for determining the clotting time are known per se to those ~killed in the art. They can, inter alia, be methods which determine the liberation of thrombin from prothrombin via the formation of a clot or the conYersion of a chromogenic substrate. The preferred method in this - connection is the chromogenic one, with a ~ery particular preference for the use of a chromogenic thrombin sub-strate, in particular of Tos-Gly-Pro-Arg-ANBA-IPA.
In a preferred embodLment of the method according to the invention, an excess of protein S-deficient plasma is added to the undiluted sample and the clotting time is then determined by admixing a reagent comprising activated protein C, an activator of the exogenous or endogenous path of clotting, phospholipids, Ca~, a chromogenic substrate for thrombin and a heparin neutralizing substance. The activated protein C can also be added to the sample separately a short time before the rest of the reagent.
2 ~ 3 ~
In a particularly preferred embodiment of the method according to the invention, the undiluted sample i6 admixed with 4 to 10 times the volume of protein S-deficient plasma. The clotting reaction is started by S admixing (5 to 10 times the sample volume of) a reagent comprising activated protein C ~1 to 50 pmol/ml), an activator of the clotting system, preferably a thrombo-plastin or a snake venom ]protease, phospholipids (5-300 ppm (w/v)), e.g. cephalin, calcium ions lQ (2-10 mmol/l), preferably CaCl2, a heparin neutralizing substancer such as e.g. Polybren (0.1-10 ~g/ml) and a chromogene thrombin substrate, such as e.g. Tos-~ly-Pro-Arg-ANBA-IPA. The time from adding the reagent to reach-ing a certain extinction (e.g. 0.1) at the absorption optimum (e.g. 405 nm) of the liberated chromophor is measured.
The activator concentration which guarantees a clotting time (without protein S) of at least 50 sec under the given reaction conditions, can in each particular case be determined by simple experiments.
Very particularly preferred methods and reagents are those described in the examples.
The clotting time is, when using a chromogenic substrate, preferably detenmined by determining the time from adding ~5 the reagent to reaching a certain extinction at the absorption optimum of the liberated chromophor. For the evaluation, a calibration curve is advantageously pre-pared by using dilutions of a pool plasma (e.g. 100~, 75~, 50%, 25%, 12.5%, 10~) in the assay and determining the clotting tLmes.
The biological sample can preferably be plasma of human origin, the use of undiluted samples being particularly preferred in this case.
A suitable protein S-deficient plasma can be obtained by - 6 - 2~7~3~
methods known per se to ~hose skilled in the art, e.g. by immunoadsorption. Factor VIII is, if necessary, adjusted by adding purified factor VIII. The factor V ~an/ if necessary, bP adjusted by adding a protein S-deficient rabbit plasma which contains large amounts of factor V.
The volume ratio of sample to protein S-deficient plasma is preferably 1:4 to 1:10.
The deficient plasma preferably has a factor V content of about 20 to 100%, particularly preferably of 50-80%.
Protein C can be purified from plasma by various pro-cesses which have been describPd (e.g. Baja~ S.P. et al.
(1983) Preparative Biochemistry 13(3) 191-214) or can be prepared by biotechnological processes. The purified protein C can be activated by means of PROTA or thrombin which have been coupled to a support material such as Sepharose(R),or activated protein C obtained directly by genetic engineering processes (Ehrlich H.J. et al., J. Biol. Chem. 264 (24) 14298-14309) can be employed. The concentration of activated pro~ein C in the assay is advantageously between 1 and 50 pmolJml.
A protein C acti~ated by a snake venom protease from the venom of Agkistrodon contortrix can preferably be employed.
Activators of the clotting system are known per se to those skilled in the art. Activators for the purpose of this invention can also be snake venom proteases and activated factors of the clotting cascade, such as e.g.
factor VIIa, factor IXa and factor Xa. Preferably, proteases from the venom of Vipera russellii, sulfatides, ellagic acid, thromboplastins and/or silica particles can be employed ~Shimada ~. et al. (1985) J. Biochem. 97, 429-439). The optimum concentration of the particular activators can be determined by simple experiments.
Phospholipids are a known class of substances which can - 7 - 2 ~3 ~ 3~
be prepared by methods known per se to those skilled in the art or are commPrcially available. Concentrations of 5-300 ppm (w/v) in the test mixture are preferred. Ca ions can advantageously be generated by adding CaCl2.
Concentrations of 2-lO mM in the test mixture are pre-ferred.
Heparin-neutralizing substances are a class of compounds known to those skilled in the art, such as e.g. Polybren, protamine chloride, protamine sulfate.
The reaction can be carried out at 15~40~C, preferably at 20-40C, very preferably at 37C.
It has been found that the protein S present in the plasma can be measured in a sensitive and specific way in the assay described (Table 1). Changes in concentration of factor VIII between 50 and 150%, of ~he vitamin ~-dependent clotting factors, such as prothrombin or protein C (50-150%), except for protein S itself, or the presence of up to 0.4 U/ml heparin have no influence. The factor V content of the sample, as expected, shows a certain influence, since Yariations in the æample cannot be completely balanced out due to the content in the protein S-deficient plasma and the inhibition of this factor is a measurement of the activity of the protein S.
The invention furthermore relates to a reagent for datermining protein S by a method according to the inven-tion, the clotting time of a æample without protein S
being at least 50 seconds.
Preferred reagents are, in this connection, those which contain a protease from the venom of Vipera russellii as activator, ancl those which contain a thromboplastin as activator.
Preferred reagents are also those which contain a chromo-genic thrombin substrate of the formula I
~3~
x-Pro-Arg-NH ~ N~2 ~I
~Nh~R
where R is Cl~-alkyl or -CH[CHtCH3~ 2 3COOCH3 and ~ is H-D-Ph~-, Boc-Gly s)r to~yl-Gly.
able 1: Specificity of the assay for the functional determination of prot~in S
Changed I Concentration ¦ Protein S activity parameter l lfound I
Control l llOo,o %
Heparin ¦0.1 U/ml ¦102 Heparin ¦0 . 2 U~ml ¦ 97 Heparin ¦0. 3 U/ml ¦109 %
Heparin ¦0. 4 U/~l ¦109 Heparin ¦0. 5 U/ml 1I32 Heparin ¦ 1. 0 U/~D1 ¦ > 150 ~6 F V ~50 % ¦ 114 %
F V ¦75 % ¦ ~11 %
F Y ¦lOQ % ¦ 100 F V ¦125 ~ ¦ 96 %
F V ¦150 ~ ¦ 91 %
F VIII ¦S0 % ¦ 106 9 F VIII ¦75 ~ ¦ 99 F VIII ¦100 % ¦ 98 F VIII ¦125 % ¦ 103 ~6 F VIII ¦lS0 % ¦ 104 ~
Protein C 1 50 % 1 96 9~i Protein C ¦100 ~ I 100 %
Protein C ¦ 150 % ¦ 103 ~6 9 ~7~3~
The following examples are intended to illustrate ~he in~ention and chall not restrict it in any way.
Example 1 Preparation of a ready-to-use reagent based on z~ aP~T
reagent 0.5 units of a~ivated protein C ~nd 10 ~9 polybrene were sdded to an aPTT
reagent (Partochrom~, Behringwerke AG, D-3550 MQxburg), comprising phospholipid, ~ulfatide, ~olybren, a chromo- -genic thrombin substrate (Tos-Gly~-Pro-~rg-AN~A-isoprop~
amide) and ~epes, pH 7.6, and the mi~ture i6 heated at 37C. The reagen~ is then ready to use.
ExEmple 2 Prep~ration of a ready-to-use reaqent based on a PT
reagent 0.5 units of activated protein C are added to a PT
reagent (Behringwerke AG, D-3550 Marburg) comprising phospholipid, thromboplastin at a low concentration, a chromogenic thrombin substrate (~os-Gly-Pro-Axg-ANBA-isopropylamide) and Hepes, p~ 7.4, and the mixture is heated at 37C. The reagent i8 then ready to use.
Example 3 Preparation ~f a ready-to-use reagent based on an activator from a snake venom 40 ng/ml of a snake venom from Vipera ru~sellii are added 2S to a buffer comprising phospholipid, a chromogenic thrombinsubstrate(Tos-Gly-Pro-Arg-AN~A-isopropylamide), a heparin ~ntagonist (Polybren), zodium chloride and Hepes, pH 7.0l and the reaction mi~ture i8 heated at 37C. ~he rea~ent i~ then ready to use.
In a particularly preferred embodiment of the method according to the invention, the undiluted sample i6 admixed with 4 to 10 times the volume of protein S-deficient plasma. The clotting reaction is started by S admixing (5 to 10 times the sample volume of) a reagent comprising activated protein C ~1 to 50 pmol/ml), an activator of the clotting system, preferably a thrombo-plastin or a snake venom ]protease, phospholipids (5-300 ppm (w/v)), e.g. cephalin, calcium ions lQ (2-10 mmol/l), preferably CaCl2, a heparin neutralizing substancer such as e.g. Polybren (0.1-10 ~g/ml) and a chromogene thrombin substrate, such as e.g. Tos-~ly-Pro-Arg-ANBA-IPA. The time from adding the reagent to reach-ing a certain extinction (e.g. 0.1) at the absorption optimum (e.g. 405 nm) of the liberated chromophor is measured.
The activator concentration which guarantees a clotting time (without protein S) of at least 50 sec under the given reaction conditions, can in each particular case be determined by simple experiments.
Very particularly preferred methods and reagents are those described in the examples.
The clotting time is, when using a chromogenic substrate, preferably detenmined by determining the time from adding ~5 the reagent to reaching a certain extinction at the absorption optimum of the liberated chromophor. For the evaluation, a calibration curve is advantageously pre-pared by using dilutions of a pool plasma (e.g. 100~, 75~, 50%, 25%, 12.5%, 10~) in the assay and determining the clotting tLmes.
The biological sample can preferably be plasma of human origin, the use of undiluted samples being particularly preferred in this case.
A suitable protein S-deficient plasma can be obtained by - 6 - 2~7~3~
methods known per se to ~hose skilled in the art, e.g. by immunoadsorption. Factor VIII is, if necessary, adjusted by adding purified factor VIII. The factor V ~an/ if necessary, bP adjusted by adding a protein S-deficient rabbit plasma which contains large amounts of factor V.
The volume ratio of sample to protein S-deficient plasma is preferably 1:4 to 1:10.
The deficient plasma preferably has a factor V content of about 20 to 100%, particularly preferably of 50-80%.
Protein C can be purified from plasma by various pro-cesses which have been describPd (e.g. Baja~ S.P. et al.
(1983) Preparative Biochemistry 13(3) 191-214) or can be prepared by biotechnological processes. The purified protein C can be activated by means of PROTA or thrombin which have been coupled to a support material such as Sepharose(R),or activated protein C obtained directly by genetic engineering processes (Ehrlich H.J. et al., J. Biol. Chem. 264 (24) 14298-14309) can be employed. The concentration of activated pro~ein C in the assay is advantageously between 1 and 50 pmolJml.
A protein C acti~ated by a snake venom protease from the venom of Agkistrodon contortrix can preferably be employed.
Activators of the clotting system are known per se to those skilled in the art. Activators for the purpose of this invention can also be snake venom proteases and activated factors of the clotting cascade, such as e.g.
factor VIIa, factor IXa and factor Xa. Preferably, proteases from the venom of Vipera russellii, sulfatides, ellagic acid, thromboplastins and/or silica particles can be employed ~Shimada ~. et al. (1985) J. Biochem. 97, 429-439). The optimum concentration of the particular activators can be determined by simple experiments.
Phospholipids are a known class of substances which can - 7 - 2 ~3 ~ 3~
be prepared by methods known per se to those skilled in the art or are commPrcially available. Concentrations of 5-300 ppm (w/v) in the test mixture are preferred. Ca ions can advantageously be generated by adding CaCl2.
Concentrations of 2-lO mM in the test mixture are pre-ferred.
Heparin-neutralizing substances are a class of compounds known to those skilled in the art, such as e.g. Polybren, protamine chloride, protamine sulfate.
The reaction can be carried out at 15~40~C, preferably at 20-40C, very preferably at 37C.
It has been found that the protein S present in the plasma can be measured in a sensitive and specific way in the assay described (Table 1). Changes in concentration of factor VIII between 50 and 150%, of ~he vitamin ~-dependent clotting factors, such as prothrombin or protein C (50-150%), except for protein S itself, or the presence of up to 0.4 U/ml heparin have no influence. The factor V content of the sample, as expected, shows a certain influence, since Yariations in the æample cannot be completely balanced out due to the content in the protein S-deficient plasma and the inhibition of this factor is a measurement of the activity of the protein S.
The invention furthermore relates to a reagent for datermining protein S by a method according to the inven-tion, the clotting time of a æample without protein S
being at least 50 seconds.
Preferred reagents are, in this connection, those which contain a protease from the venom of Vipera russellii as activator, ancl those which contain a thromboplastin as activator.
Preferred reagents are also those which contain a chromo-genic thrombin substrate of the formula I
~3~
x-Pro-Arg-NH ~ N~2 ~I
~Nh~R
where R is Cl~-alkyl or -CH[CHtCH3~ 2 3COOCH3 and ~ is H-D-Ph~-, Boc-Gly s)r to~yl-Gly.
able 1: Specificity of the assay for the functional determination of prot~in S
Changed I Concentration ¦ Protein S activity parameter l lfound I
Control l llOo,o %
Heparin ¦0.1 U/ml ¦102 Heparin ¦0 . 2 U~ml ¦ 97 Heparin ¦0. 3 U/ml ¦109 %
Heparin ¦0. 4 U/~l ¦109 Heparin ¦0. 5 U/ml 1I32 Heparin ¦ 1. 0 U/~D1 ¦ > 150 ~6 F V ~50 % ¦ 114 %
F V ¦75 % ¦ ~11 %
F Y ¦lOQ % ¦ 100 F V ¦125 ~ ¦ 96 %
F V ¦150 ~ ¦ 91 %
F VIII ¦S0 % ¦ 106 9 F VIII ¦75 ~ ¦ 99 F VIII ¦100 % ¦ 98 F VIII ¦125 % ¦ 103 ~6 F VIII ¦lS0 % ¦ 104 ~
Protein C 1 50 % 1 96 9~i Protein C ¦100 ~ I 100 %
Protein C ¦ 150 % ¦ 103 ~6 9 ~7~3~
The following examples are intended to illustrate ~he in~ention and chall not restrict it in any way.
Example 1 Preparation of a ready-to-use reagent based on z~ aP~T
reagent 0.5 units of a~ivated protein C ~nd 10 ~9 polybrene were sdded to an aPTT
reagent (Partochrom~, Behringwerke AG, D-3550 MQxburg), comprising phospholipid, ~ulfatide, ~olybren, a chromo- -genic thrombin substrate (Tos-Gly~-Pro-~rg-AN~A-isoprop~
amide) and ~epes, pH 7.6, and the mi~ture i6 heated at 37C. The reagen~ is then ready to use.
ExEmple 2 Prep~ration of a ready-to-use reaqent based on a PT
reagent 0.5 units of activated protein C are added to a PT
reagent (Behringwerke AG, D-3550 Marburg) comprising phospholipid, thromboplastin at a low concentration, a chromogenic thrombin substrate (~os-Gly-Pro-Axg-ANBA-isopropylamide) and Hepes, p~ 7.4, and the mixture is heated at 37C. The reagent i8 then ready to use.
Example 3 Preparation ~f a ready-to-use reagent based on an activator from a snake venom 40 ng/ml of a snake venom from Vipera ru~sellii are added 2S to a buffer comprising phospholipid, a chromogenic thrombinsubstrate(Tos-Gly-Pro-Arg-AN~A-isopropylamide), a heparin ~ntagonist (Polybren), zodium chloride and Hepes, pH 7.0l and the reaction mi~ture i8 heated at 37C. ~he rea~ent i~ then ready to use.
3 ~
Example 4 Determination of the protein S conten~ in plasma For the calibration, 100%, 75%, 50~, 25%, 10% and 0%
dilutions of a healthy-donor plasma are prepared in phosphate-buffered isotonic saline. The measurement of the standards and the samples is carried out as described below:
10 ~1 of sample 50 ~1 of protein S-deficient plasma 500 ~1 of reagent according to a) Example 1 b) Example 2 are pipetted into a cuvette.
When adding the reagent, a clock is started and the extinction at 405 nm i~ monitored until an increase in the ab~orption by a certain value (e.g. of 0.1) has been reached. ~he prolongation of the clotting time beyond the value for 0~ protein S is proportional to the concentra-tion of protein S in the sample (Fig. 1).
The data for the determination according to the method described in DE 37 24 443 have been taken from German Offenlegungsschrift DE 37 24 443 Al, Figure 1.
Example 5 Determination of the protein S content in plasma when separately adding activated protein C
For the calibration, 100%, 75%, 50%, 25%, 10% and 0%
dilutions of a healthy-donor plasma are prepared in saline. The measurement of the standards and the samples is carried out as described below:
3 ~
10 ~1 of sample 50 ~1 of pxotein S-deficient plasma 25 ~1 of activated protein C
500 ~1 of reagent according to Example 3 are pipetted into a cuvette.
On adding the reagent, a clock .is started and either the extinction at 405 nm is monito:red until an increase in absorption by a certain value (e.g. of 0.1) has been reached, or the occurrence of clot formation is measured.
The prolongation of the clotting time beyond the value for 0% protein S is proportional to the concentration of protein S in the sample (Fig. 2). ,-
Example 4 Determination of the protein S conten~ in plasma For the calibration, 100%, 75%, 50~, 25%, 10% and 0%
dilutions of a healthy-donor plasma are prepared in phosphate-buffered isotonic saline. The measurement of the standards and the samples is carried out as described below:
10 ~1 of sample 50 ~1 of protein S-deficient plasma 500 ~1 of reagent according to a) Example 1 b) Example 2 are pipetted into a cuvette.
When adding the reagent, a clock is started and the extinction at 405 nm i~ monitored until an increase in the ab~orption by a certain value (e.g. of 0.1) has been reached. ~he prolongation of the clotting time beyond the value for 0~ protein S is proportional to the concentra-tion of protein S in the sample (Fig. 1).
The data for the determination according to the method described in DE 37 24 443 have been taken from German Offenlegungsschrift DE 37 24 443 Al, Figure 1.
Example 5 Determination of the protein S content in plasma when separately adding activated protein C
For the calibration, 100%, 75%, 50%, 25%, 10% and 0%
dilutions of a healthy-donor plasma are prepared in saline. The measurement of the standards and the samples is carried out as described below:
3 ~
10 ~1 of sample 50 ~1 of pxotein S-deficient plasma 25 ~1 of activated protein C
500 ~1 of reagent according to Example 3 are pipetted into a cuvette.
On adding the reagent, a clock .is started and either the extinction at 405 nm is monito:red until an increase in absorption by a certain value (e.g. of 0.1) has been reached, or the occurrence of clot formation is measured.
The prolongation of the clotting time beyond the value for 0% protein S is proportional to the concentration of protein S in the sample (Fig. 2). ,-
Claims (15)
1. A method for determining protein S by determining the clotting time in a biological sample, wherein the amount of added activators is adjusted in such a way that the clotting time is prolonged beyond the normal clotting time.
2. The method as claimed in claim 1, wherein an excess of protein S-deficient plasma is added to the sample and, after admixing a reagent comprising an activator of clotting, calcium ions, phospholipids, activated protein C, an inhibitor of heparin and, if appropriate, a chromogenic peptide substrate for thrombin, the time is measured until a defined increase in extinction at the absorption optimum of the free chromophor is reached or clotting occurs.
3. The method as claimed in claim 1, wherein the sample is initially introduced together with an excess of protein S-deficient plasma and, after separately adding activated protein C by adding a reagent comprising an activator of clotting, calcium ions, phospholipids, an inhibitor of heparin and a chromo-genic peptide substrate for thrombin, the time is measured until a defined increase in extinction at the absorption optimum of the free chromophor is reached or clotting occurs.
4. The method as claimed in claim 1, wherein the undiluted sample is admixed with 4 to 10 times the volume of protein S-deficient plasma, the clotting reaction is started by admixing (5 to 10 times the sample volume) of a reagent comprising activated protein C (1 to 50 pmol/ml), an activator of the clotting system, preferably a thromboplastin or a snake venom protease, phospholipids (5-300 ppm (w/v)), e.g. cephalin, calcium ions (2-10 mmol/l) preferably CaCl2, a heparin-neutralizing substance, such as e.g. Polybren (0.1-10 µg/ml), and a chromo-genic thrombin fiubstrate, such as e.g. Tos-Gly-Pro-Arg-ANBA-IPA. The time from adding the reagent to reaching a certain extinction (e.g. 0.1) at the absorption optimum (e.g. 405 nm) of the liberated chromophor is measured.
5. The method as claimed in claim 1, wherein the clotting tIme is determined with the aid of a chromogenic substrate.
6. The method as claimed in claim 1, wherein the deficient plasma has a factor V content of 20 to 100%.
7. The method as claimed in claim 1, wherein the protein C was activated by a snake venom protease from the venom of the snake Agkistrodon contortrix.
8. A reagent for the functional determination of protein S by determining the clotting time in a biological sample, wherein the clotting time in the absence of protein S is at least 50 seconds.
9. The reagent as claLmed in claLm 8, which contains, inter alia:
activated protein C, an activator of the exogenous or endogenous path of clotting, phospholipids, calcium ions, if appropriate a chromogenic substrate for thrombin, and a heparin-neutralizing supstance.
activated protein C, an activator of the exogenous or endogenous path of clotting, phospholipids, calcium ions, if appropriate a chromogenic substrate for thrombin, and a heparin-neutralizing supstance.
10. The reagent as claimed in claim 8, wherein the activator is a protease from the venom of a snake or the refractionated snake venom.
11. The reagent as claimed in claim 8, wherein a throm-boplastin is used as activator.
12. The reagent as claimed in claLm 8, wherein the - 14 _ activator is a sulfatide or a mixture of sulfatides.
13. The reagent as claimed in claim 8, wherein the heparin inhibitor i Polybren.
14. The reagent as claimed in claim 8, wherein chromogenic thrombin substrate used is a compound of the formula I
(I) where R is C1-5-alkyl or -CH[CH(CH3)2]COOCH3 and X is H-D-Phe-, Boc-Gly or Tosyl-Gly.
(I) where R is C1-5-alkyl or -CH[CH(CH3)2]COOCH3 and X is H-D-Phe-, Boc-Gly or Tosyl-Gly.
15. A method for determining protein S as claimed in claim 1 and substantially as described herein.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DEP4006634.7 | 1990-03-03 | ||
| DE4006634A DE4006634A1 (en) | 1990-03-03 | 1990-03-03 | FUNCTIONAL TEST TO DETERMINE PROTEIN S ACTIVITY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2037434A1 true CA2037434A1 (en) | 1991-09-04 |
Family
ID=6401312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002037434A Abandoned CA2037434A1 (en) | 1990-03-03 | 1991-03-01 | Functional assay for determining the protein s activity |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0445626B1 (en) |
| JP (1) | JPH04350560A (en) |
| AT (1) | ATE147861T1 (en) |
| AU (1) | AU652737B2 (en) |
| CA (1) | CA2037434A1 (en) |
| DE (2) | DE4006634A1 (en) |
| DK (1) | DK0445626T3 (en) |
| ES (1) | ES2097158T3 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5780255A (en) * | 1995-06-09 | 1998-07-14 | Instrumentation Laboratory, S.P.A. | Protein C pathway screening test |
| US6855509B2 (en) | 2000-12-19 | 2005-02-15 | Instrumentation Laboratory Company | Protein S functional assay and kit therefor |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5308756A (en) * | 1991-11-20 | 1994-05-03 | Baxter Diagnostics Inc. | Protein S chromogenic assay |
| DE60139572D1 (en) * | 2000-12-19 | 2009-09-24 | Instrumentation Lab Co | FUNCTIONAL ASSAY FOR PROTEIN S |
| JP2009198506A (en) * | 2009-04-10 | 2009-09-03 | Shino Test Corp | Activity measuring method and activity measuring reagent for blood-clotting reaction inhibitory plasma protein |
| JP2011133396A (en) * | 2009-12-25 | 2011-07-07 | Sysmex Corp | Activated partial thromboplastin time measuring reagent, activated partial thromboplastin time measuring method, and determination method for determining presence or absence of blood coagulation inhibitor |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3311287A1 (en) * | 1983-03-28 | 1984-10-04 | Behringwerke Ag, 3550 Marburg | METHOD FOR PHOTOMETRICALLY DETERMINING THE ACTIVATED PARTIAL THROMBOPLASTIN TIME AND REAGENT TO IT |
| DE3413311A1 (en) * | 1984-04-09 | 1985-10-17 | Behringwerke Ag, 3550 Marburg | REAGENT FOR DETERMINING THROMBOPLASTIN TIME |
| JPS62159048A (en) * | 1986-01-03 | 1987-07-15 | Eiken Kagaku Kk | Method for measuring bioactivity of protein s |
| DE3607559A1 (en) * | 1986-03-07 | 1987-09-10 | Boehringer Mannheim Gmbh | METHOD FOR PHOTOMETRICALLY DETERMINING THE PROTEIN C AND / OR PROTEIN S ACTIVITY |
| JPS6450960A (en) * | 1987-08-21 | 1989-02-27 | Yamanouchi Pharma Co Ltd | Quantitative measuring method of active type protein s |
| IT1230744B (en) * | 1989-07-07 | 1991-10-29 | Instrumentation Lab Spa | METHOD FOR DETERMINING THE FUNCTIONAL ACTIVITY OF PROTEIN S IN HUMAN PLASMA. |
| SE464135B (en) * | 1989-07-14 | 1991-03-11 | Kabivitrum Ab | PROCEDURE FOR DETERMINING THE FUNCTIONAL ACTIVITY OF FREE PROTEIN S OR PROTEIN C IN A PLASMA TEST |
-
1990
- 1990-03-03 DE DE4006634A patent/DE4006634A1/en not_active Withdrawn
-
1991
- 1991-02-26 DK DK91102805.8T patent/DK0445626T3/en active
- 1991-02-26 DE DE59108478T patent/DE59108478D1/en not_active Revoked
- 1991-02-26 AT AT91102805T patent/ATE147861T1/en not_active IP Right Cessation
- 1991-02-26 EP EP91102805A patent/EP0445626B1/en not_active Revoked
- 1991-02-26 ES ES91102805T patent/ES2097158T3/en not_active Expired - Lifetime
- 1991-03-01 JP JP3057633A patent/JPH04350560A/en active Pending
- 1991-03-01 CA CA002037434A patent/CA2037434A1/en not_active Abandoned
- 1991-03-01 AU AU71983/91A patent/AU652737B2/en not_active Ceased
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5780255A (en) * | 1995-06-09 | 1998-07-14 | Instrumentation Laboratory, S.P.A. | Protein C pathway screening test |
| US6855509B2 (en) | 2000-12-19 | 2005-02-15 | Instrumentation Laboratory Company | Protein S functional assay and kit therefor |
| US7468257B2 (en) | 2000-12-19 | 2008-12-23 | Instrumentation Laboratory Corporation | Protein S functional assay |
| US8334108B2 (en) | 2000-12-19 | 2012-12-18 | Instrumentation Laboratory Company | Kit for protein S functional assay |
Also Published As
| Publication number | Publication date |
|---|---|
| DK0445626T3 (en) | 1997-06-23 |
| EP0445626A3 (en) | 1992-06-03 |
| EP0445626A2 (en) | 1991-09-11 |
| ATE147861T1 (en) | 1997-02-15 |
| DE4006634A1 (en) | 1991-09-05 |
| ES2097158T3 (en) | 1997-04-01 |
| DE59108478D1 (en) | 1997-02-27 |
| AU652737B2 (en) | 1994-09-08 |
| AU7198391A (en) | 1991-09-05 |
| JPH04350560A (en) | 1992-12-04 |
| EP0445626B1 (en) | 1997-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4784944A (en) | Prothrombin time determining reagent and methods of using and preparing the same | |
| US7118880B2 (en) | Kits for screening for blood coagulation disorders | |
| AU751525B2 (en) | Method for determining the anticoagulatory potential of a sample | |
| US20090087870A1 (en) | Hematological assay and kit | |
| US5726028A (en) | Method for detecting disturbances of the protein c/protein s system | |
| Bertina et al. | Spectrophotometric assays of prothrombin in plasma of patients using oral anticoagulants | |
| AU6053390A (en) | A method for determining the functional activity of free protein s or protein c in a plasma sample | |
| Vinazzer et al. | Protein C: comparison of different assays in normal and abnormal plasma samples | |
| US4918001A (en) | Method for the determination of protease inhibitors | |
| Friberger | Synthetic peptide substrate assays in coagulation and fibrinolysis and their application on automates | |
| EP0567636B1 (en) | Protein s assay | |
| Marlar et al. | Hereditary dysfunctional protein C molecules (type II): assay characterization and proposed classification | |
| CA2037434A1 (en) | Functional assay for determining the protein s activity | |
| EP0436654A1 (en) | Immunoassays for catalytically-active, serine proteases | |
| Enfield et al. | Cleavage and activation of human factor IX by serine proteases | |
| Goodnight JR et al. | Measurement of antithrombin III in normal and pathologic states using chromogenic substrate S-2238: comparison with immunoelectrophoretic and factor Xa inhibition assays | |
| CA2421957C (en) | Method for measuring antithrombin activity | |
| US5753510A (en) | Calibrator for use in test methods for detecting a defective coagulation factor V | |
| US6100050A (en) | Factor VIII:Ca chromogenic assay | |
| AU654962B2 (en) | Factor VIII:Ca chromogenic assay | |
| Budzynski | Chromogenic substrates in coagulation and fibrinolytic assays | |
| Mitchell | Development and clinical use of automated synthetic substrate methods for the evaluation of coagulation and fibrinolysis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |